Drugs / OZ1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01177059 | Dec 2004 → Nov 2017 | — | Janssen-Cilag Pty Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00074997 | Dec 2002 → Jan 2008 | — | Janssen-Cilag Pty Ltd | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OZ1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00074997 ↗ |
| Action | Inhibit | “The gene therapy OZ1 is thought to have anti-HIV-1 actions.” NCT01177059 ↗ |
| Modality | Oligonucleotide (other) | “a tat-vpr-specific anti-HIV ribozyme (OZ1)” PMID 19219022 ↗ Feb 2009 |
| Route | Intravenous | “Single intravenous infusion of OZ1.” NCT00074997 ↗ |